TEVA

Teva Pharmaceutical Industries Ltd

Add to Watchlist

Advanced Chart

16.420

+0.05(0.305%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

16.540

Open

16.280

VWAP

16.42

Vol

7.52M

Mkt Cap

18.83B

Low

16.280

Amount

123.51M

EV/EBITDA(TTM)

7.10

Total Shares

1.13B

33.89B

EV/OCF(TTM)

24.38

P/S(TTM)

1.13

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

3.98B

+2.18%

0.563

+8.33%

4.45B

+5.33%

0.712

+0.31%

4.35B

+0.34%

0.675

-2.23%

Estimates Revision

The market is revising Downward the revenue expectations for Teva Pharmaceutical Industries Limited (TEVA) for FY2025, with the revenue forecasts being adjusted by -0.74% over the past three months. During the same period, the stock price has changed by -8.57%.

Revenue Estimates for FY2025

Revise Downward

-0.74%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.5%

In Past 3 Month

Stock Price

Go Down

-8.57%

In Past 3 Month

7 Analyst Rating

38.55% Upside

Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 22.75 USD with a low forecast of 15.50 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

38.55% Upside

Current: 16.420

Low

15.50

Averages

22.75

High

29.00

38.55% Upside

Current: 16.420

Low

15.50

Averages

22.75

High

29.00

Piper Sandler

Overweight

downgrade

$30 -> $29

2025-07-29

Reason

Piper Sandler

Price Target

$30 -> $29

2025-07-29

downgrade

Overweight

Reason

Piper Sandler lowered the firm's price target on Teva to $29 from $30 and keeps an Overweight rating on the shares ahead of quarterly results. The firm says performance for biopharma in Q2 and into Q3 thus far has seen marked improvement, in part a function of fears surrounding tariff-related dislocation receding into the background, in part a function of fears regarding pricing-related dislocation also receding into the background, and in part a function of an anticipated more favorable rate environment. With that said, Piper believes that choppy waters, or perceptions thereof, will continue to render profitable bigger caps as something of a safer haven.

UBS

Buy

maintain

$24 -> $23

2025-06-26

Reason

UBS

Price Target

$24 -> $23

2025-06-26

maintain

Buy

Reason

UBS lowered the firm's price target on Teva to $23 from $24 and keeps a Buy rating on the shares. Despite steady execution progress on its mid- and long-term outlook, shares are down 20% year-to-date, and UBS thinks the stock has been penalized more unfairly than most of the rest of biopharma. Teva management has addressed multiple investor concerns by stabilizing U.S. generics, rekindling Austedo growth from a sleeper, proved R&D execution, and solving the Revlimid cliff, the analyst tells investors in a research note.

Evercore ISI

Outperform

initiated

2025-06-21

Reason

Evercore ISI

Price Target

2025-06-21

initiated

Outperform

Reason

Evercore ISI initiated coverage of MedinCell (MDCLF) with an Outperform rating and no price target. The French biotech company specializing in long-acting injectable formulation technology earns revenue through royalties on worldwide net sales of partnered drugs as well as through licensing fees and milestones and has become "an increasingly popular partner-of-choice" for big pharma companies, the analyst tells investors. Currently partnered with Teva (TEVA) on their LAI atypical antipsychotics used in schizophrenia, Uzedy royalties will get them to profitability in 2027, but the main focus is on LAI olanzapine, which is expected to launch into a market with essentially zero competition in 2026, if approved, the analyst tells investors.

Goldman Sachs

initiated

$24

2025-06-06

Reason

Goldman Sachs

Price Target

$24

2025-06-06

initiated

Reason

Goldman Sachs initiated coverage of Teva with a Buy rating and $24 price target. The firm sees an improving core business, with upside to near-mid-term consensus EBITDA estimates driven by "strong growth" in the branded segment. Goldman's estimates are 6% above consensus EBITDA estimates in 2027 and it sees the potential for this to expand further on continued execution. Teva's pipeline optionality represents a "significant valuation lever," adds the firm.

Truist

initiated

$25

2025-05-27

Reason

Truist

Price Target

$25

2025-05-27

initiated

Reason

Truist initiated coverage of Teva with a Buy rating and $25 price target. Teva's dual focus on cultivating its high-margin brands while strengthening generics continues to de-risk the topline and margin profile, says the analyst, who sees management executing well against the company's "Pivot to Growth" plan. The firm sees potential line of sight to 30% operating margin by 2027, the analyst added.

Moody's Investor Services

Ba2 -> Ba1

upgrade

2025-05-15

Reason

Moody's Investor Services

Price Target

2025-05-15

upgrade

Ba2 -> Ba1

Reason

Teva Pharmaceuticals "announced that Moody's Investor Services has raised the company's corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive. Moody's report cites the Company's strengths which include significant global scale, ongoing growth in the company's branded franchises, stabilization of the company's generics business, focus on debt reduction and resolution of various legal liabilities."

See All Ratings

Valuation Metrics

The current forward P/E ratio for Teva Pharmaceutical Industries Ltd (TEVA.N) is 6.30, compared to its 5-year average forward P/E of 4.50. For a more detailed relative valuation and DCF analysis to assess Teva Pharmaceutical Industries Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Overvalued

5Y Average PE

4.50

Current PE

6.30

Overvalued PE

5.92

Undervalued PE

3.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

6.89

Current EV/EBITDA

6.87

Overvalued EV/EBITDA

7.39

Undervalued EV/EBITDA

6.40

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

0.81

Current PS

1.11

Overvalued PS

1.05

Undervalued PS

0.56

Financials

Annual

Quarterly

FY2025Q2

YoY :

+0.29%

4.18B

Total Revenue

FY2025Q2

YoY :

+8.06%

952.00M

Operating Profit

FY2025Q2

YoY :

-132.08%

281.00M

Net Income after Tax

FY2025Q2

YoY :

-132.00%

0.24

EPS - Diluted

FY2025Q2

YoY :

+1771.43%

131.00M

Free Cash Flow

FY2025Q2

YoY :

+3.19%

51.70

Gross Profit Margin - %

FY2025Q2

YoY :

+28.54%

5.36

FCF Margin - %

FY2025Q2

YoY :

-132.30%

6.78

Net Margin - %

FY2025Q2

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

1.9M

USD

3-6

Months

9.1M

USD

6-9

Months

11.4M

USD

0-12

Months

327.1K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

2.6M

Volume

6-9

Months

12.4M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

31.0M

Volume

Months

6-9

16.8M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

1.9M

USD

3-6

Months

9.1M

USD

6-9

Months

11.4M

USD

0-12

Months

327.1K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

TEVA News & Events

Events Timeline

2025-08-06 (ET)

2025-08-06

07:26:38

Teva announces U.S. FDA has approved AJOVY for preventive treatment

2025-07-30 (ET)

2025-07-30

08:27:13

Teva says targeting operating margin of 30% by 2027

2025-07-30

08:19:53

Teva says 'very confident' about growing generics business

News

7.0

07-30Benzinga

Teva Pharma Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy

7.0

07-30SeekingAlpha

Teva raises 2025 EPS outlook and innovative product guidance as company targets $700M in cost savings by 2027

3.0

07-30NASDAQ.COM

Teva Pharmaceutical Industries Q2 25 Earnings Conference Call At 8:00 AM ET

People Also Watch

Tyler Technologies Inc

BROOKFIELD ASSET MANAGEMENT LTD

Archer-Daniels-Midland Co

Huntington Bancshares Inc

American Water Works Co Inc

145.550

USD

+0.13%

FAQ

What is Teva Pharmaceutical Industries Ltd (TEVA) stock price today?

The current price of TEVA is 16.42 USD — it has increased 0.31 % in the last trading day.

TEVA

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

TEVA News & Events

Events Timeline

News

People Also Watch

FAQ

What is Teva Pharmaceutical Industries Ltd (TEVA) stock price today?

What is Teva Pharmaceutical Industries Ltd (TEVA)'s business?

What is the price predicton of TEVA Stock?

What is Teva Pharmaceutical Industries Ltd (TEVA)'s revenue for the last quarter?

What is Teva Pharmaceutical Industries Ltd (TEVA)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Teva Pharmaceutical Industries Ltd (TEVA)'s fundamentals?

How many employees does Teva Pharmaceutical Industries Ltd (TEVA). have?

What is Teva Pharmaceutical Industries Ltd (TEVA) market cap?